Review Article

Roles of miRNAs and long noncoding RNAs in the progression of diabetic retinopathy

Qiaoyun Gong and Guanfang Su
Eye Center, The Second Hospital of Jilin University, #218 Ziqiang Street, Changchun, Jilin 130021, China

Correspondence: Guanfang Su (sugf2012@163.com)

Diabetic retinopathy (DR) is the leading cause of blindness in working-age adults across the world. The pathogenesis of DR is multifactorial and the molecular mechanisms are still not fully understood. Accumulating evidence has demonstrated that noncoding RNAs (ncRNAs) may be aberrantly expressed and may play vital roles in the development of DR. Amongst ncRNAs, miRNAs and long ncRNAs (lncRNAs) are known for their regulatory functions. Here, we summarize the functions and mechanisms of known aberrantly expressed miRNAs and lncRNAs, their applications as diagnostic or prognostic biomarkers, and their potential therapeutic targets. In conclusion, this review will help us gain a better understanding of the molecular mechanisms by which miRNAs and lncRNAs perform their functions in DR, and provide general strategies and directions for future research.

Introduction

Diabetes mellitus (DM), defined by a fasting plasma glucose value of ≥7.0 mmol/l (126 mg/dl) or by receiving medication for raised blood glucose, is increasingly common and prevalent across the world. Diabetes poses a well-recognized increased risk for cardiovascular disease, kidney failure, blindness, and lower-limb amputation [1]. Diabetic retinopathy (DR) is one of the most serious microvascular complications and is the leading cause of visual disability and blindness in working-age adults (20–65 years) [2]. DR stems from abnormal retinal blood vessels that are either non-proliferative (non-proliferative DR (NPDR)) or proliferative (proliferative DR (PDR)). Visual impairment results from edema affecting the central retina or macula (diabetic macular edema (DME)). Thus, DR is the most common vision-threatening complication of DM and is the prime cause of visual loss in diabetic patients [3,4].

The microvascular circulation of the retina is predominantly affected by DM, resulting in a range of structural changes. These changes ultimately cause increased permeability and altered proliferation of endothelial cells (ECs), edema, and abnormal neovascularization (NV) of the retina, leading to vision loss [5]. The pathogenesis of DR is extremely complicated, implicating numerous different mechanisms. A previous study has shown that consistently elevated blood glucose in the retina can cause oxidative stress [6], characterized by excess reactive oxygen species (ROS) activating the four canonical pathways that damage retinal cells and tissues [7]. Inflammation is another important factor contributing to the progression of DR in the early stage [8]. During this stage of diabetes, the enhanced secretion of proinflammatory cytokines renders the retina a sustained inflammatory environment, ultimately resulting in retinal microvascular abnormalities [9]. Neuronal dysfunction is also detected in the progress of DR [10]. DM affects neurones via altered metabolism, which leads to apoptosis of the retinal ganglion cells (RGC) and activation of glial cells. Metabolic alterations are likely to be mediated by oxidative stress, inflammation, and elevated levels of
glutamate [11]. In summary, oxidative stress and enhanced production of inflammatory mediators, accompanied by neurodegeneration, contribute to the pathogenesis and complexity of DR. In addition to the metabolic changes, hyperglycemic insult also affects the enzymatic machinery responsible for epigenetic modifications; these modifications alter gene expression without affecting the DNA sequence [12]. Epigenetics could be one of the major contributing participants in the development and progression of DR, but the role of epigenetics in DR is still in its incipient stages. The epigenetic modifications, including DNA methylation, histone modifications, and miRNAs regulation, alter and aggravate the progression of DR in spite of the controlled glucose [13]. Overall, epigenetics is an emerging area, and the diabetic environment favors epigenetic modifications; the genes implicated in the pathogenesis of DR and enzymes responsible for epigenetic modifications and miRNAs are altered in the retina in diabetes, suggesting the role of these post-translational modifications in the progression of DR. These mechanisms may interact closely, creating a network that leads to pathologic changes in the retina, including disruption of vascular integrity, increased vascular permeability, and retinal NV.

Amongst the pathways participating in the pathogenesis and progression of DR, a large number of related protein-encoding genes have been identified and shown to play crucial roles in vascular changes. These factors include vascular endothelial growth factor (VEGF) [14], pigment epithelium derived factor (PEDF) [15], angiopoietin [16], and bone morphogenetic protein (BMP) [17]. In addition to protein-coding genes, and unlike the known RNA molecules that perform infrastructural and housekeeping roles (such as tRNAs, rRNAs, and snoRNAs), recent data suggest that enormous numbers of so-called noncoding RNAs (ncRNAs), having little to no protein-coding potential, are expressed and function in the pathogenesis of DR [18-20]. ncRNAs are divided into distinctive classes mainly according to origin, structure, and biological functions. In recent decades, miRNAs, a group of small ncRNAs, have been broadly studied in the different pathways involved in the pathogenesis of DR. Moreover, a novel class of transcripts called long ncRNAs (lncRNAs), which are pervasively transcribed in the genome, is gaining attention because of their potential regulatory roles in the progression and prevention of DR.

In this review, we will focus on discussing miRNAs, lncRNAs, and their potential biological roles and underlying molecular mechanisms in the pathogenesis and development of DR. Finally, we will discuss the prospects of using miRNAs and lncRNAs as potential biomarkers and therapeutic targets for the treatment of DR. This review will help us gain a better understanding of the molecular mechanisms, by which miRNAs and lncRNAs perform their functions and interactions in DR, and will provide direction for future research.

Roles of miRNAs in DR

Biogenesis and functions of miRNAs

miRNAs are a group of short (approximately 21–23 nts long) and highly conserved sequences of endogenous RNAs that do not code for any protein. miRNAs modulate gene expression through transcriptional and post-transcriptional regulation, inducing mRNA degradation or inhibiting protein translation by binding to the seed region on the 3′-UTR of target genes. They are expressed in all human cell types and are involved in main biological processes such as cell growth, differentiation, and apoptosis [4,21,22].

The synthesis of miRNAs is a complex biological process involving several enzymes located in both the nuclear and cytoplasmic compartments of cells. The coding region for miRNAs may be embedded within the intronic genomic regions of both coding and noncoding genes or within exons. Similar to mRNAs, transcription occurs in the nucleus, mediated by RNA polymerase II, leading to the generation of primary miRNAs (pri-miRNAs). pri-miRNAs are long (>1000 nts), capped, polyadenylated primary transcripts that contain specific loop–stem structures called hairpins. In the canonical processing pathway, pri-miRNAs are recognized and cleaved by the protein complex Drosha/DGCR8 (DiGeorge syndrome critical region gene 8), resulting in shorter nucleotide sequences (70–100 nts) known as pre-miRNAs [23,24]. Once synthesized, pre-miRNAs are recognized by the nuclear–cytoplasmic shuttle protein Exportin-5 and are transferred to the cytoplasm. Then, pre-miRNAs are processed by the RNase III protein Dicer, leaving shorter (21–23 nts) double-stranded RNA sequences. These sequences contain the mature miRNA and its passenger strand. The guide strand is then joined to one of the Argonaute (Ago) proteins to establish the core of the silencing complex called the RNA-induced silencing complex (RISC); the passenger strand is discarded and degraded [25]. The mature RISC can bind the UTR, generally the 3′-UTR. The so-called ‘seed region’, spanning between nucleotides 2 and 8 of the 5′-end of the mature miRNA, binds a complementary sequence in the 3′-UTR of target mRNAs. The complementary sequence, positioned between the seed region and mRNA-binding sites on the 3′-UTR, is necessary for target recognition [21]. However, several studies have shown that miRNA targeting is not always limited to the 3′-UTR, with respect to the 5′-UTR of mRNAs. There are naturally occurring examples of miRNA down-regulating the expression of the corresponding mRNA in a seed-dependent manner [26]. Finally,
miRNA–mRNA binding leads to translational inhibition or degradation of the target mRNA. It is clear that the ultimate biological effect on cells occurs via the repression of specific proteins involved in a particular biological pathway.

A single miRNA may modulate the expression of several mRNAs; conversely, more than 60% of mRNAs have predicted binding sites for multiple miRNAs, thus allowing concomitant interaction with multiple miRNAs [27]. It is, therefore, expected that the function and biogenesis of miRNAs can be regulated, because their alteration is associated with a wide range of human diseases, including chronic conditions.

**Dysregulated miRNAs in DR**

As described above, miRNAs play vital roles in the proliferation, migration, and apoptosis of human cells, including retinal cells. It is not surprising that miRNAs have been reported to play an important role in regulating DR-related NV. An uncontrolled high level of blood glucose is the leading cause of type 2 DM and related complications. DR is a chronic and serious eye complication associated with DM, presenting microvascular and macrovascular changes. In the early stage of DR, human retinal ECs (HRECs) and retinal pigment epithelial (RPE) cells, which are components of the blood–retinal barrier (BRB), are affected and impaired by the adverse effects of high glucose (HG); this induces dysfunction of BRB and contributes to progression of DR [28-31]. To date, numerous studies have investigated the roles of miRNAs in DR, using HRECs and RPE cells as in vitro and in vivo models of streptozotocin (STZ)-induced diabetic retinas.

Kovacs et al. [32] identified a series of miRNAs whose expression is altered in the retinas of diabetic rats. This provided the first insight into the roles of miRNAs in the pathogenesis of DR. miRNA array profiling has revealed that in retinas of diabetic rats, the expression of 80 miRNAs was significantly increased, and expression of 6 miRNAs was decreased, compared with that of controls. In the retinas of diabetic rats, 16 miRNAs were up-regulated (P < 0.01) and 104 miRNAs were down-regulated compared with those in controls (P < 0.01). Furthermore, the same study identified NF-κB-, VEGF-, and p53-responsive miRNAs. The up-regulation of miR-146, miR-155, miR-132, and miR-21 in the retinas of diabetic rats is known to be NF-κB-responsive, suggesting an miRNA signature in NF-κB activation in diabetic retinas. Additionally, VEGF-responsive miRNAs (miR-17-5p, miR-18a, miR-20a, miR-21, miR-31, and miR-155) are up-regulated in both retinas and retinas of diabetic rats when the level of VEGF is increased. This implies that these miRNAs may be involved in the progression of DR partly through mediating functions of VEGF. The miR-34 family, including miR-34a/b/c, is a direct transcriptional target of p53 and contributes to p53-mediated cell-cycle arrest, apoptosis, and senescence [33]. In the diabetic retina, the levels of p53-responsive miR-34 family become elevated in response to the activation of p53. This suggests that the miR-34 family plays a role in the p53-mediated apoptosis in neuroretinal and ECs, thus, contributing to the progression of DR. Wu et al. [34] has reported a significantly altered expression of miRNAs in the retinas of STZ-induced diabetic rats 10 weeks after injection with STZ. Microarray profiles and real-time PCR analyses indicate that a total of 11 miRNAs (miR-182, miR-96, miR-183, miR-211, miR-204, miR-124, miR-135b, miR-592, miR-190b, miR-363, and miR-29c) show increased expression, whereas 6 miRNAs (miR-10b, miR-10a, miR-219-2-3p, miR-144, miR-338, and miR-199a-3p) are found at decreased levels, in the retinas of DM rats compared with those in normal controls. The variation in the expression levels of some retinal miRNAs parallels the course of DR, suggesting a close association between miRNA dysregulation and the development of DR. Xiong et al. identified 17 dysregulated miRNAs, in the retinas of STZ-induced diabetic rats, 10 weeks after the onset of DM [35]. GO analysis revealed that the most prevalent miRNAs are related to olfactory bulb development, axonogenesis, and mitogen-activated protein and calcium signaling pathways. An additional six miRNAs (miR-203, -350, -212, -216a, -410, and -34c) were further validated by RT-qPCR. These six miRNAs are at the core of a network and are most likely to have the most significant regulatory functions [35]. The expression levels of miR-216a-5p, -34c-5p, -410-3p, and -203a-3p are significantly up-regulated in the DM group compared with that in the control group, while miR-212-3p is down-regulated, and miR-350 shows no significant change. Additionally, in our recent study, we identified several miRNAs, both in HRECs and ARPE-19 cells, whose levels increase with time under hyperglycemia; the levels of these miRNAs also increase in the retinas of STZ-induced DM rats for 4, 6, and 8 weeks after STZ injection [36]. Amongst the identified miRNAs, miR-124-3p, miR-125b-5p, miR-135b-5p, and miR-199a-5p showed a gradually decreased expression in HRECs and RPE cells; this paralleled an increase in hyperglycemia-treatment time. miR-145-5p and miR-146a-5p exhibited the opposite changes in expression (down-regulation in HRECs and up-regulation in RPE cells) in response to HG exposure over increasing durations. In the retinas of DM rats, miR-124-3p and miR-125b-5p remain down-regulated during the different stages of DR, while miR-135b-5p, miR-145-5p, miR-146a-5p, and miR-199a-5p show increased expression that parallels

mir-29c was produced from the opposite arm of the precursor, while miR-29c was the predominant product.
the progression of DR. These findings imply that the same miRNAs may vary, and play opposite roles, during DR development. The underlying reason for these differences can be explained by the fact that the pathological changes, associated with DR progression, and the intrinsic variability of DR etiogenesis, exert distinct effects on miRNA biogenesis, resulting in either up-regulation or down-regulation at different stages of DR. Much of this discrepancy may also be due to different sample sizes and different laboratory techniques.

**Specific miRNAs and their targets in different pathways involved in DR**

miR-200b has been the most studied miRNA since it was first discovered. In ECs, treated with HG and in the retinas of STZ-induced diabetic rats 1 month after the onset of diabetes, the expression of miR-200b is decreased, whereas its validated direct target, VEGF, is increased at both the mRNA and protein levels [37]. Overexpression of miR-200b ameliorates VEGF expression in the retinas of diabetic rats and prevents glucose-induced increased permeability and angiogenesis in human umbilical vein ECs (HUVECs). Conversely, an miR-200b antagonist can increase VEGF production, further demonstrating the role of this miRNA in the pathogenesis of DR. However, another study, performed in a genetic model of type 1 diabetes (Akita mice), found that the expression of miR-200b increases significantly in 8-month-old diabetic rats compared with that in controls [38]. Increased expression of miR-200b inhibits the expression of oxidation resistance 1 (Oxr1), a protective gene involved in resistance to apoptosis and oxidative stress. Moreover, the level of miR-200b is decreased in HRECs in an HG environment, and is accompanied by increased levels of VEGF and transforming growth factor β (TGF-β1). miR-200b regulates the proliferation of HRECs by altering VEGF and TGF-β1 expression, thus delaying DR [39]. The levels of miR-200b and VEGFA mRNA, in the sera of DR patients, indicate that DR patients show decreased expression of miR-200b and increased VEGFA mRNA in comparison with those in healthy people [40]. Another study found that the expression of miR-200b is increased in the vitreous samples from eyes with PDR compared with those of controls (P<0.001). Vitreous VEGF expression is also significantly higher in the PDR group than in the control group (P<0.001); however, no significant correlation is found between miR-200b and VEGF [41]. According to these studies, miR-200b is down-regulated in ECs under HG, in the retinas of STZ-induced diabetic rats and in the sera of DR patients, whereas it is up-regulated in the retinas of Akita mice and vitreous of PDR patients. These discrepancies in the expression of miR-200b may have multiple causes. The first cause may be due to the use of different diabetic models, including cultured retinal cells, STZ-induced DM rats, the Akita mouse model, and serum or vitreous samples from DR patients. Another reason may be due to differences in the duration of diabetes, which may also contribute to the variability in the results. Additionally, the pathological changes, associated with DR progression, may exert distinct effects on miRNA biogenesis, resulting in either up-regulation or down-regulation at different stages of DR.

**miR-146**

miR-146 was first implicated in DR when its roles were investigated in the modulation of the NF-κB inflammatory response. NF-κB is a ubiquitous inducible transcription factor and key modulator of cellular inflammatory pathways, playing a role in the early phases of DR development [42]. The increased level of miR-146a, in the RECs of diabetic rats, is transactivated by NF-κB. The increased level of miR-146a also exerts negative feedback on IL-1R/toll-like receptor (TLR) mediated NF-κB activation by targeting IL-1 receptor associated kinase 1 (IRAK1) and tumor necrosis factor (TNF) receptor associated factor 6 (TRAF6) [32]. IRAK1 and TRAF6 are downstream members of the myeloid differentiation primary-response protein-88 (MyD88)-dependent IL-1R/TLR-mediated NF-κB activation pathway in monocytes [43]. Cowan et al. [44] has uncovered a novel negative feedback regulatory mechanism, involving thrombin-induced and G-protein-coupled receptor (GPCR) mediated activation of NF-κB by miR-146, which targets caspase-recruitment domain (CARD) containing protein 10 (CARD10) in HRECs. Recently, Ye et al. demonstrated that the expression of miR-146a was down-regulated in HRECs cultured in HG 45[]. Overexpression of miR-146a reduced the levels of TLR4/NF-κB and TNF-α, and inhibited the MyD88-dependent and -independent pathways in RECs, under hyperglycemic conditions [45]. These results indicate that miR-146a can play a negative regulatory role in multiple pathways of NF-κB activation, which are related to inflammatory processes in DR. Furthermore, miR-146a reduces the expression of NF-κB-responsive adhesion molecule intercellular adhesion molecule-1 (ICAM-1) by binding to the 3′-UTR of IRAK1, an upstream adapter protein activated by IL-1β in both HRECs and diabetic rat retinas [46]. miR-146a and IRAK1 exhibit daily oscillations in antiphase; however, these patterns are lost in the diabetic retina. The loss of the rhythmic pattern is associated with an increase in ICAM-1, IL-1β, and VEGF expression, and contributes to the progression of DR. A following study, performed in vivo, to confirm the regulatory role of miR-146a in the NF-κB-responsive proinflammatory pathway, has shown that intravitreal injection of lenti-miR-146a increases the expression of miR-146a in the retina, while its key downstream target genes,
including CARD10, IRAK1, and TRAF6, are down-regulated [47]. Intravitreal delivery of miR-146 inhibits the diabetes-induced up-regulation of the NF-κB downstream gene ICAM1, microvascular leakage, and retinal functional defects. These results indicate that miR-146 may be an alternative therapeutic target for the treatment of DR via inhibition of NF-κB. Moreover, a decrease in the level of miR-146a, and the overexpression of fibropectin (FN), are observed in HG-treated ECs and retinas of STZ-induced diabetic rats at 1 month of DM [48]. FN is an extracellular matrix (ECM) protein, and its increased production is a characteristic feature of all chronic complications in diabetes. miR-146a can regulate FN directly by binding to the 3′-UTR of FN; therefore, the up-regulation of miR-146a may be a key mechanism for ameliorating the increased production of ECM proteins in diabetes. Recently, another pathway, involving miR-146a, indicated that miR-146a is down-regulated in HRECs under HG. However, elevated expression of miR-146a resulted in inhibition of signal transducer and activator of transcription 3 (STAT3) and VEGF signaling via down-regulation of IL-6 in HRECs under HG conditions. This suggests that miR-146a can protect HRECs from HG-induced apoptosis by suppressing the STAT3/VEGF pathway via IL-6 signaling [49].

The association of miR-146a with inflammation in DR may also involve miR-146b. Anti-inflammatory processes may be induced by extracellular adenosine that activates adenosine receptors. Extracellular adenosine is regulated by the interplay of the equilibrative nucleoside transporter with adenosine deaminase (ADA) and adenosine kinase. In the vitreous of diabetic patients, decreased miR-146b-3p is associated with increased ADA2 activity. Elevated expression of miR-146b-3p suppresses the expression and activity of ADA2, and TNF-α release, in amadori-glycated albumin (AGA) treated human macrophages. These results suggest that by suppressing ADA2, miR-146b-3p plays a regulatory role in diabetes-related retinal inflammation [50]. A following study investigated the role of miR-146b-3p in HRECs. They found that miR-146b reverses the changes in AGA-treated macrophages, significantly increasing HREC permeability, rescuing the disrupted pattern of zonula occludens (ZO)-1, and increasing leukocyte adhesion to HRECs by up-regulating ICAM-1. Therefore, inhibition of ADA2 by miR-146b-3p may be a useful tool for preserving the BRB function in DR [51].

miR-126

Down-regulation of miR-126 is observed in the retinas of oxygen-induced retinopathy (OIR) mice. Retinal NV is a key pathological alteration in PDR, leading to dramatic vision loss; it is mediated by numerous angiogenic factors such as VEGF, insulin/insulin-like growth factor (IGF), and hypoxia-inducible factor-1α (HIF-1α). The restoration of miR-126 levels ameliorates the high levels of VEGF, IGF, and HIF-1α, resulting in reduction in retinal NV under ischemic conditions. The production of angiogenic factors, regulated by miR-126, may depend on p38 and extracellular signal regulated kinase (ERK), both enzymes of the mitogen-activated protein kinase (MAPK) pathway. In the ischemic retina, reduced levels of miR-126 may stimulate the activation of p38 and ERK pathways, and increase the expression of angiogenic factors downstream [52]. Ye et al. has confirmed the down-regulation of miR-126 in hypoxia-induced R6/6A cells in vitro and in diabetic retinas of STZ-induced diabetic rats 3 months after the onset of diabetes. Restoration of miR-126 expression halts the hypoxia-induced NV by suspending cell-cycle progression and inhibiting the expression of VEGF and matrix metalloproteinase 9 (MMP-9) [53]. Furthermore, miR-126 is down-regulated in human retinal pericytes under conditions of intermittent HG. Extracellular vesicles (EVs), derived from mesenchymal stem cells (MSCs) maintained under diabetes-like conditions, may play a role in vessel destabilization, thus contributing to angiogenesis through paracrine signaling. MSC-derived EV, obtained under hyperglycemic/hypoxic conditions, down-regulate the expression of miR-126 in pericytes, leading to increased expression of angiogenic molecules such as VEGF and HIF-1α. These results suggest that miR-126 potentially plays a role in EV-induced vessel destabilization in DR [54]. Clinically, a significant decrease in the serum expression of miR-126 is detected in diabetic patients with complications (especially those with diabetic macrovascular complications and DR) compared with the levels of those without evident complications. Serum expression of miR-126 may be a good marker for diagnosing type 2 DM and for monitoring the outcomes of this disease [55]. Similarly, in a large cohort of type 1 diabetic patients, the levels of miR-126 were significantly lower than those in controls, and were associated with vascular complications of diabetes, particularly with proliferative retinopathy [56].

Other miRNAs

Up-regulation of miR-29b was first detected in the retinas of diabetic rats within 35 days after STZ injection. Proapoptotic RNA-dependent protein kinase (PKR) associated protein X (RAX) is indirectly regulated by miR-29b [57]. miR-29b and RAX are localized in the RGCs and the cells of the inner nuclear layer (INL) in the retinas of normal and STZ-induced diabetic rats. The up-regulation of miR-29b, in the early stage of STZ-induced DM rats, may have a protective effect against apoptosis in RGCs and cells of the INL via the proapoptotic PKR pathway. Moreover, in an in vitro study, Lin et al. observed that miR-29 is up-regulated by HG in RPE cells [58]. Down-regulation of
miR-29 protects against HG-induced apoptosis via direct targeting of phosphatase and tensin homolog (PTEN), and reduced production of caspase-7 in RPE cells [58]. miR-29a is decreased in diabetic retinas with overexpressed angiotensigen (AGT). Up-regulation of miR-29a inhibits the high levels of AGT and significantly ameliorates the vascular density, tortuosity, and EC nuclei [59]. AGT is part of the renin–angiotensin system, which exists in various organs, participates in the occurrence and progression of a variety of diseases, and is linked with diabetes [60]. Therefore, miR-29a may prevent the development of DR in the rat model via down-regulation of AGT.

Mortuza et al. [61] demonstrated that up-regulation of miR-195 in HRECs exposed to HG and in the retinas of diabetic rats is accompanied by a concomitant down-regulation of silent information regulator protein 1 (SIRT1). Glucose-induced increased oxidative stress causes rapid aging in ECs and retinas in diabetes; these processes are mediated via alteration of SIRTs. Neutralization of miR-195 rescues SIRT1 expression directly and decreases tissue damage in DR, highlighting a potential role of miR-195-SIRT1 signaling in modulation of REC function. Consistent with these findings, oxidative stress induced overexpression of miR-195 causes direct down-regulation of mitofusin 2 (MFN2) in HRECs and diabetic retinas, leading to tube formation and increased permeability of retinal BRB, which are two common pathogenic functional changes associated with DR [62]. MFN2 is a multifunctional mitochondrial membrane protein associated with oxidative stress and diabetes-related complications [63]. Therefore, miR-195 may be a potential therapeutic target because it regulates molecules associated with oxidative stress in the progression of DR. SIRT1 is also a direct target of miR-23b-3p, which is elevated by HG in HRECs. Reduced expression of miR-23b-3p inhibits the expression of acetylated NF-kB by rescuing the expression of SIRT1, and relieves the effect of metabolic memory induced by HG, in HRECs. These results were confirmed in the retina of a diabetic rat model of metabolic memory. Therefore, miR-23b-3p regulates HG-induced cellular metabolic memory in DR through a SIRT1-dependent signaling pathway [64].

Kovacs et al. [32] identified an increased level of the miR-34 family in the retinas and RECs of diabetic rats in vivo. However, Hou et al. confirmed the down-regulation of miR-34a in subconfluent ARPE-19 cells [65]. The proliferative and migratory phenotype of RPE cells occur under pathological conditions such as DR. Up-regulation of miR-34a can inhibit the proliferation and migration of RPE cells by inhibiting its target, c-Met, and other cell cycle related molecules such as CDK2, CDK4, CDK6, E2F1, and p-Cdc2 [65]. Furthermore, up-regulation of miR-34a inhibits the proliferation, migration, and attachment of RPE cells, partly by down-regulating the expression of leucine-rich repeat containing GPCR 4 (LR4) and inducing reduced expression levels of cell cycle mediators E2F1, p-CDC2, CDK2, CDK4, and CDK6 [66].

The expression of miR-15b and miR-16 is reduced in HRECs cultured under hyperglycemic conditions for 3 days. Overexpression of miR-15b and miR-16 inhibits the levels of TNF-α and suppressor of cytokine signaling 3 (SOCS3), while increasing that of IGF-binding protein-3 (IGFBP-3) and the phosphorylation of insulin receptor (IR) Tyr150/151. This shows that miR-15b and miR-16 play a role in the inhibition of insulin resistance, resulting in HREC protection from hyperglycemia-induced apoptosis [67]. In addition to investigating the regulatory effects of miR-15a and miR-16 on insulin resistance, Ye et al. has confirmed that miR-15a and miR-16 play inhibitory roles in proinflammatory signaling, reducing retinal leukostasis in DR [68]. Hyperglycemia induces the down-regulation of miR-15a and miR-16, while overexpression of miR-15a and miR-16 significantly decreases proinflammatory signaling of IL-1β, TNF-α, and NF-kB in HRECs under conditions of HG. An in vivo study, using knockout mice in which miR-15a and miR-16 are eliminated in the vascular ECs, has shown that the loss of miR-15a and miR-16 leads to increased retinal leukostasis and levels of CD45, as well as up-regulated levels of IL-1β, TNF-α, and NF-kB. Therefore, miR-15a and miR-16 may play significant roles in reducing retinal leukostasis, potentially through inhibition of inflammatory cellular signaling [68]. Wang et al. has reported on the dual anti-inflammatory and anti-angiogenic actions of miR-15a in DR [69]. miR-15a is reduced in the retina and bone marrow cells in diabetes. Inhibition of miR-15a up-regulates the expression of acid sphingomyelinase (ASM), a proinflammatory molecule, and that of VEGFA, an angiogenic molecule, in RPE and ECs; this is accompanied by impairment of migration and retinal vascular repair function. In the animal model of overexpressed miR-15a, ASM and VEGFA levels are directly reduced to nondiabetic levels; diabetes-induced increased retinal permeability is also prevented in these mice [69]. These studies indicate that miR-15 may be modulating multiple pathologies in DR.

The up-regulation of miR-21 and miR-155 is NF-kB responsive in RECs and retinas of diabetic rats [32]. Another study found that inhibition of miR-21 significantly enhances the HG-induced endothelial cytotoxicity. Further, over-expression of miR-21 inhibits the expression of death domain associated protein (DAXX), a proapoptotic mediator, whereas silencing DAXX mRNA reverses the inhibitory effects of miR-21 on HG-induced endothelial apoptosis; this indicates that miR-21 can protect ECs from apoptosis by inhibiting the expression of DAXX [70]. Recently, it was found that increased levels of miR-21 in the vitreous are associated with retinal fibrosis, including PDR and proliferative vitreoretinopathy (PVR). The expression of miR-21 in RPE cells, under HG conditions, is enhanced
and induced by TGF-β, suggesting that its role positively correlates with disease progression. Furthermore, gain- and loss-of-function studies have revealed that miR-21 promotes proliferation and migration of ARPE-19 cells. The present study indicates that miR-21 is a potential disease-modifying miRNA in the vitreous humor and is involved in the development of retinal fibrosis [71]. miR-155 is involved in immunomodulatory signaling [72]. The expression levels of miR-155 in the peripheral blood of patients with PDR are significantly increased compared with those in the negative control (NC) group; the percentage of Treg cells, and the expression levels of TGF-β, are significantly decreased in PDR patients. The expression of miR-155 is negatively correlated with the amount of Treg cells and the expression level of TGF-β, suggesting that miR-155 may play a role in the pathogenesis of T2DM retinopathy [73].

The levels of a number of growth and vasoactive factors, especially VEGF, are increased in response to hyperglycemia. Dysfunction of ECs is the primary cellular pathology in complications of chronic diabetes. ECs undergo functional alterations that cause NV in response to VEGF. Hence, VEGF-mediated alterations are of significance in the early (vascular permeability), as well as late (NV), stages of DR. An increasing number of miRNAs are discovered and investigated in the regulation of VEGF in DR. Ling et al. [74] demonstrated a cross-talk between HIF-1α and VEGF via interactions with 12 common miRNAs in ARPE-19 and RPE cells isolated from mice. Silencing HIF-1α or VEGF increases the availabilities of shared miRNAs. Up-regulation of a common miRNA (miR-106a) significantly decreases the expression of HIF-1α and VEGF, and prevents HG-induced increased permeability, in an in vivo animal model of type 1 DM. Because VEGF and HIF-1α play important roles in the progression of DR and other retinal diseases, such cross-talk may have significant therapeutic implications [74]. Similarly, miRNA-dependent cross-talk between VEGF and angiopoietin-2 (Ang-2) was investigated. Ang-2 and VEGF are involved in the regulation of angiogenesis and are commonly regulated by miR-351. miR-351-dependent cross-talk between VEGF and Ang-2 occurs in hypoxic RF/6A cells and in rat retinas. Overexpression of miR-351 significantly reduces the high levels of VEGF and Ang-2 in vitro and in an in vivo OIR animal model. Overall, miR-351-dependent cross-talk between Ang-2 and VEGF plays a role in the microvascular response induced by hypoxia [75]. Further, VEGF can be modulated by RAC-γ serine/threonine-protein kinase 3 (AKT3), which is targeted by miR-20b in DR. miR-20b is down-regulated, while AKT3 and VEGF are elevated in HRECs under HG conditions. Overexpression of miR-20b inhibits AKT3, and the silencing of AKT3 causes a decrease in the levels of VEGF, preventing an HG-induced increase in transendothelial permeability and tube formation. The regulating effect of miR-20b, on the mediation of VEGF by AKT3, has been confirmed in vivo in STZ-induced diabetic rats. This indicates that miR-20b directly targets AKT3 and modulates VEGF-mediated changes in DR [76]. Wu et al. found that the decrease in miR-18b, in HG-induced HRECs, promotes cell proliferation and production of VEGF [77]. Further, miR-18b performs its function by targeting IGF-1 directly. Stimulation of IGF-1 antagonizes the effect induced by up-regulation of miR-18b, promoting cell proliferation and increased VEGF production. The opposite is observed upon silencing of IGF-1, which is consistent with the effects of miR-18b overexpression. miR-18b exerts its function on VEGF synthesis and cell proliferation by suppressing the IGF-1 receptor (IGF1R) pathway, consequently inhibiting the downstream molecules. Thus, miR-18b can attenuate the expression of VEGF, and proliferation of HG-induced HRECs, by suppressing the IGF-1/IGF1R signaling pathway; this has potential clinical significance [77].

Genes of the let-7 family are the founding members of miRNAs, with established functions in tissue differentiation and tumor suppression [78,79]. The role of the let-7 gene family in angiogenesis, related to DR and age-related macular degeneration (AMD), was first investigated by Zhou et al. [80]. The let-7 family genes are expressed in HRECs, choroidal ECs, and ARPE-19. Overexpression of let-7 in vivo leads to features of NPDR, including tortuous retinal vessels and defective pericyte coverage; however, this phenotype does not progress to PDR. Overexpression of let-7 represses the proliferation, migration, and networking of ECs, while inhibition of let-7 has the opposite effect. Moreover, let-7 transgenic mice exhibit significantly reduced NV in the choroid after laser injury, while inhibition of let-7, using the let-7 anti-miR, strongly enhances choroidal NV (CNV). The study indicates that let-7 contributes to NPDR, but represses angiogenesis and CNV, in vivo.

### Aberrant miRNAs as biomarkers in serum and vitreous humor of patients with DM

Circulating miRNAs have emerged as novel biomarkers of diabetes. Cells release miRNAs into the circulation or their surrounding environment, where miRNAs have a long lifespan of more than 2 weeks. Hirota et al. [81] first investigated the expression of 168 miRNAs in the vitreous humor and serum samples of patients with PDR and macular hole. This study found that six miRNAs (miR-15a, miR-320a, miR-320b, miR-93, miR-29a, and miR-423-5p), related to angiogenesis and fibrosis, are significantly overexpressed in PDR [81]. Zampetaki et al. [81] evaluated 300 serum samples from two DR-related randomized, double-blind, parallel-design, placebo-controlled clinical trials
Roles of IncRNAs in DR
The biology of IncRNAs
In recent years, advancements in genome-wide analyses of the mammalian transcriptome have revealed a novel class of transcripts, IncRNAs, which are pervasively transcribed in the genome [85]. IncRNAs stand for a class of RNA molecules that are fundamentally different from miRNAs in their functions and actions. Unlike the short sequences of miRNAs, the transcripts for IncRNAs are usually longer than 200 nt and can even reach more than 100 kb [86]. The transcripts for IncRNAs lack significant ORFs and are localized in both the nucleus and cytoplasm [87,88]. Similar to protein-coding genes, the transcription of IncRNAs can be regulated, showing specific temporal and cell-type-specific expression [89,90]. The majority of IncRNAs are transcribed from the nuclear, or less frequently, from the mitochondrial, genome. The primary transcript can also be modified post-transcriptionally, similar to conventional mRNA modifications, including 5′ capping, 3′ polyadenylation, and splicing [85,87]. As a result of their prolonged length and sequence, the transcripts of IncRNAs can form specific secondary structures with clear functional features [91,92]. They modulate cellular gene expression at multiple levels and may act as signals, decoys, guides, and scaffolds [93]. IncRNAs may guide transcription factors to, or sequester them from, a specific region of action, or they may interact with multiple components, thereby repressing or activating gene expression [94]. Through intricate mechanisms, they play significant roles in various biological processes, including cell differentiation, apoptosis, nuclear trafficking, heat shock response, and more. An increasing number of studies have identified IncRNAs as a new class of modulatory molecules that participate in various human diseases by regulating gene expression at the transcriptional, post-transcriptional, or epigenetic level [95]. IncRNAs can induce or reduce protein translation via alternative splicing, turnover, export, and translocation of mRNAs. They can reduce the effect of miRNAs on mRNA stability by acting as competing endogenous RNAs (ceRNAs) or RNA sponges when they contain an miRNA-binding sequence region. Thus, the role of IncRNAs, in the pathogenesis of DR, deserves to be explored and investigated. Here, we review the aberrant IncRNAs and summarize the specific identified IncRNAs in DR (Table 1).

Aberrant expression of IncRNAs in DR
The profiling of IncRNA expression in the retinas of STZ-induced diabetic mice was first performed using microarray analysis by Yan et al. [20]. In this study, approximately 303 IncRNAs were differentially expressed in the retinas with early DR; these included 214 down-regulated IncRNAs and 89 up-regulated IncRNAs. GO analysis indicated that these IncRNAs coexpressed mRNAs are related to the development of the eye, integral to membrane and structural molecular activity. Pathway analysis indicated that IncRNAs coexpressed mRNAs are involved in several pathways, including axon guidance, MAPK signaling pathway, complement and coagulation cascades, chemokine signaling pathway, and pyruvate metabolism. These signaling pathways are closely associated with pathological processes, such as neurodegeneration, NV, inflammation, and immunology, suggesting that the IncRNA-mediated network plays an extensive role in the pathogenesis of DR. Furthermore, metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), a highly conserved IncRNA, is significantly overexpressed in RF/6A cells under hyperglycemic conditions, as well as in aqueous humor samples and fibrovascular membranes of diabetic patients. This implies that IncRNAs are involved in the pathogenesis of DR via modulation of multiple pathogenic pathways.
Table 1 Dysregulated IncRNAs involved in DR

| LncRNA   | Dysregulation | Tissues and cell type                | Pathogenic functions                                                                 | Possible mechanism                                                                 | References |
|----------|---------------|--------------------------------------|--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|------------|
| MIAT     | Up-regulated  | Retinas of DM rats; RF/6A, RPE, RGC and Müller cells | Promotes EC proliferation, migration, and tube formation in vitro                   | NF-κB activation                                                                   | [96-98]    |
|          |               |                                      | Aggravates retinal vessel impairments and visual dysfunction in vivo                  | Cross-talks with p38 MAPK signaling pathway                                         | [99-101]   |
| MALAT1   | Up-regulated  | Retinas of DM mice; RF/6A             | Promotes EC proliferation, migration, and tube formation in vitro                   | Activates inflammatory pathway via TNF-α and IL-6                                    | [102]      |
|          |               |                                      | Deteriorates retinal NV in vivo                                                     |                                                                                      |            |
| MEG3     | Down-regulated| Retinas of DM mice; RF/6A             | Regulates ECI proliferation, migration, and tube formation in vitro                 | Activates PI3K-Akt signaling pathway                                                 | [103]      |
|          |               |                                      | Aggravates retinal vessel dysfunction in vivo                                        |                                                                                      |            |
| SOX2OT   | Down-regulated| Retinas of DM mice; RGCs              | Decreases cell viability and increases cell apoptosis in vitro                      | Antioxidative via regulation of Nrf2/HO-1 signaling activity                           | [104,105]  |
|          |               |                                      | Promotes neurodegeneration in vivo                                                  |                                                                                      |            |
| RNCR2    | Up-regulated  | Retinas of DM mice; RF/6A, Muller cells | Increases cell viability and proliferation, promotes EC migration and tube formation in vitro | Related to the release of several cytokines                                          | [106]      |
|          |               |                                      | Aggravates retinal cell apoptosis, visual function, and microvascular leakage in vivo |                                                                                      |            |
| ANRIL    | Up-regulated  | Retinas of DM mice; HRECs             | Increases retinal microvascular permeability in vivo                                | Increases VEGF mediated by PRC2 complex and p300                                     | [107,108]  |
| BDNF-AS  | Up-regulated  | ARPE-19                               | Increases cell apoptosis in vitro                                                  | Not only via BDNF-associated pathways                                               |            |

Abbreviations: ANRIL, antisense RNA to INK4 locus; BDNF-AS, brain-derived neurotrophic factor antisense; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; MEG3, maternally expressed gene 3; MIAT, myocardial infarction associated transcript; NRF2/HO-1, nuclear factor erythroid 2 related factor 2/heme oxygenase-1; PRC2, polycomb repressor complex 2; RNCR2, retinal ncRNA 2; SOX2OT, SOX2 overlapping transcript.

A three-stage genome-wide association study (GWAS) was conducted to identify susceptible long intergenic ncRNAs in DR amongst the Japanese population [109]. A total of 837 type 2 diabetes patients with DR (cases) and 1149 individuals without DR (controls) were enrolled in the study. After the three-stage GWAS, the top signal, found in this association analysis, was rs9362054 in an intron of RP1-90L14.1, showing borderline genome-wide significance. While RP1-90L14.1 is a long intergenic ncRNA (lincRNA), adjacent to the KIAA1009/QN1/CEP162 gene, CEP162 plays a critical role in the formation of the ciliary transition zone before cilogenesis. The present study raised the possibility that the dysregulation of ciliary-associated genes plays a role in susceptibility to DR.

**Potential functional IncRNAs in DR**

MIAT

Myocardial infarction associated transcript (MIAT), also known as Gomafu or retinal ncRNA 2 (RNCR2), was first indicated as a susceptibility locus for myocardial infarction [96] and found to be highly expressed in retinal precursor cells [97]. Yan et al. [98] has shown that MIAT expression is strongly up-regulated in the retinas of diabetic rats and in FVMs from PDR patients. Consistently, HG conditions induced high levels of MIAT in RF/6A ECs, RPE cells, RGCs, and Mueller cells in vitro. In turn, knockdown of MIAT improves visual functions, under diabetic conditions, by inhibiting apoptosis. MIAT down-regulation alleviates retinal vessel impairment, in vivo, by reducing vascular leakage and counteracting the DM-induced up-regulation of proinflammatory proteins such as ICAM-1, TNF-α, and VEGF. MIAT knockdown in vitro, in ECs, inhibits EC proliferation, migration, and tube formation under diabetic conditions. Because MIAT is involved in the different stages of DR, MIAT knockdown is therapeutically effective.
against neovascular diseases [110]. MIAT is overexpressed in Muöller cells, isolated from STZ-induced DM mice, and in rat retinal Muöller cells (rMC-1) with HG; this is accompanied by the up-regulation of p-p65, indicating increased activity of NF-κB. ChIP results have revealed that HG promotes the binding activity between NF-κB and MIAT, indicating that NF-κB selectively binds to the MIAT promoter [99].

MALAT1
MALAT1 is highly expressed in different kinds of tumors, including lung cancer, liver cancer, renal cell carcinoma, bladder cancer, and osteosarcoma; it also participates in the pathogenesis of DR [100]. MALAT1 is significantly up-regulated in the retinas of diabetic mice, in HG-treated RF/6A cells, and in the aqueous humor samples and fibrovascular membranes of diabetic patients [20]. Liu et al. found that MALAT1 regulates REC function and pathological microvascular growth under diabetic conditions [101]. MALAT1 knockdown ameliorates DR in vivo and regulates EC functions (cell proliferation, migration, and tube formation) in vitro via cross-talk between MALAT1 and the p38 MAPK signaling pathway [101]. Michalik et al. [111] found that MALAT1 levels are significantly increased by hypoxia and controlled by a phenotypic switch in ECs. Silencing of MALAT1 induces a promigratory response and increases basal sprouting and migration, whereas proliferation of ECs is inhibited. In vivo studies have confirmed that genetic ablation of MALAT1 inhibits the proliferation of ECs and reduces neonatal retina vascularization. Pharmacological inhibition of MALAT1 reduces blood flow recovery and capillary density after hindlimb ischemia. In conclusion, the knockdown of MALAT1 can tip the balance from a proliferative to a migratory EC phenotype in vitro; its genetic deletion, or pharmacological inhibition, reduces vascular growth in vivo. Puthaveetil et al. [112] investigated whether MALAT1 can regulate inflammatory pathways that involve inflammatory cytokines in diabetes. The increased levels of MALAT1, induced by HG, are associated with a parallel increase in serum amyloid antigen 3 (SAA3), an inflammatory ligand and target of MALAT1, and are further accompanied by an increase in the inflammatory mediators TNF-α and IL-6. Thus, MALAT1 participates in inflammatory activation by up-regulating TNF-α and IL-6 via SAA3 in ECs under hyperglycemic conditions.

MEG3
Maternally expressed gene 3 (MEG3) is a noncoding transcript belonging to the imprinted DLK1-MEG3 locus on chromosome 14q32.3 in humans. MEG3 is expressed in many normal tissues [113,114], but its expression is lost in several human tumors and tumor cell lines. The MEG3 gene region, on chromosome 14q32.2, alters susceptibility to type 1 diabetes [102]. Epigenetic regulation of the DLK1-MEG3 miRNA cluster is altered in human type 2 diabetic islets [115]. This evidence implies a potential role of MEG3 in the pathological processes of DM. Qiu et al. [116] showed that the MEG3 expression level was significantly down-regulated in the retinas of STZ-induced diabetic mice and ECs under conditions of HG and oxidative stress. Silencing of MEG3 aggravated retinal vessel dysfunction in vivo, as shown by severe capillary degeneration, increased microvascular leakage, and inflammation. The knockdown of MEG3 also contributes to REC proliferation, migration, and tube formation in vitro. The roles of MEG3, in ECs, are mediated by the activation of the PI3K-Akt signaling pathway. Thus, up-regulation of MEG3 may serve as a therapeutic strategy for treating diabetes-related microvascular complications.

SOX2OT
SOX2 overlapping transcript (SOX2OT) is an IncRNA localized on human chromosome 3q26.33. Within one of its introns, SOX2OT holds the single-exon SOX2 gene, overlapping in the same transcriptional orientation [117]. In humans, SOX2OT is highly enriched in the brain [103]. The retina and optic nerve are part of the brain; the eye and the brain share a number of common features [118]. Thus, SOX2OT may also be involved in the regulation of retinal neural function, thereby affecting retinal neurodegeneration. Li et al. [119] demonstrated that SOX2OT expression is significantly down-regulated in the retinas of STZ-induced diabetic mice, and in the RGCs, under HG or oxidative stress. SOX2OT knockdown protects RGCs against HG-induced injury in vitro, reversing the decreased cell viability and increased cell apoptosis induced by HG. Moreover, SOX2OT knockdown is neuroprotective in diabetes-related retinal neurodegeneration in vivo, playing an antioxidative role via regulation of nuclear factor erythroid 2 related factor 2/heme oxygenase-1 (NRF2/HO-1) signaling activity in vitro and in vivo. These results indicate that SOX2OT may be a promising therapeutic target for the prevention and treatment of diabetes-induced neural retinal neurodegeneration.

RNCR3
Retinal ncRNA3 (RNCR3), also known as LINC00599, was initially identified as an IncRNA expressed during mouse retinal development. RNCR3 was reported to be involved in neuronal and oligodendrocyte differentiation [104], and
in atherosclerosis-related vascular dysfunction [105]. Emerging evidence indicates that retinal neurodegeneration, including neural apoptosis and reactive gliosis, is an important pathological feature of DR. Liu et al. [120] demonstrated that RNR3 knockdown significantly inhibits retinal reactive gliosis. HG significantly up-regulates the expression of RNR3 in Müller cells. Inhibition of RNR3 leads to a marked reduction in the release of several cytokines, including IL-2, IL-3, IL-4, IL-5, IL-9, IL-13, IL-17, MCP-1, VEGF, and TNF-α. RNR3 knockdown alleviates DM-induced retinal neurodegeneration in vivo, as shown by the reduction in apoptotic retinal cells and improved visual function. RNR3 knockdown also decreases the viability and proliferation of Müller glial cells and reduces the expression of glial reactivity related genes, including GFAP and vimentin, in vitro. These results indicate that RNR3 knockdown inhibits retinal glial reactivity and prevents HG-induced retinal neurodegeneration.

Consistent with the previous study, Shan et al. [121] also confirmed that RNR3 is significantly up-regulated, under Hg stress, in RF/6A cells, retinas of diabetic mice, and FVMs from PDR patients. RNR3 knockdown significantly alleviates DM-induced retinal microvascular leakage in vivo and inhibits migration and tube formation by RF/6A cells under HG stress. According to these results, RNR3 inhibition may be a treatment option for the prevention of DR-related retinal abnormalities.

ANRIL
Antisense RNA to INK4 locus (ANRIL) is important in cardiovascular diseases, type 2 diabetes, glaucoma, intracranial aneurysm, and cancers [122–125]. ANRIL consists of 19 exons, spanning 126.3 kb and producing a 3.8-bp RNA. It is situated in the p15/CDKN2B-p16/CDKN2A-p14/ARF gene cluster [126]. ANRIL may exert direct transcriptional effects, or play an indirect role, as a recruiter of chromatin remodeling complexes, such as polycomb repressor complex 2 (PRC2), to specific genomic loci [127,106]. Overexpression of ANRIL has also been shown to regulate the histone acetylase p300 [128]. Thomas et al. [129] demonstrated that HG and diabetes cause ANRIL up-regulation in HRECs and in the retina of diabetic animals, which is accompanied by an up-regulation of VEGF. The overexpression of VEGF is prevented by ANRIL siRNA transfection, showing a direct regulatory relationship. In vivo studies, using ANRIL knockout mice, have revealed that diabetes-induced up-regulation of retinal VEGF, and increased retinal microvascular permeability, are prevented by the down-regulation of ANRIL. Mechanistic studies found that ANRIL up-regulates VEGF via PRC2 components and p300 in glucose-exposed ECs and in the retinal tissue of diabetic animals. In summary, the regulatory effect of ANRIL on VEGF is mediated by interaction of ANRIL with components of the PRC2 complex, and histone acetylase p300, under diabetic conditions.

BDNF-AS
The lncRNA brain-derived neurotrophic factor antisense (BDNF-AS) is a natural antisense RNA of BDNF. BDNF-AS is naturally expressed in various human tissues, and may possibly have neural functions that are opposite to those of BDNF [130]. BDNF is expressed at low levels in animal models of, and patients with, DR [107,108]. The effects of BDNF-AS on apoptosis, in the progression of DR, were first investigated by Li et al. [131]. BDNF and BDNF-AS are inversely regulated by d-glucose-induced apoptosis, in which BDNF is significantly down-regulated, and BDNF-AS is up-regulated, by 50 mM d-glucose in ARPE-19 cells. Down-regulation of BDNF-AS ameliorates glucose-induced apoptosis in ARPE-19 and inversely up-regulates BDNF at both RNA and protein levels. BDNF-AS can directly target the binding sequence of BDNF, and regulate BDNF-associated cytokines, such as TNF-α and ILs [132]. Moreover, silencing of BDNF reverses the protective effect of BDNF-AS down-regulation on glucose-induced apoptosis; however, inhibition of BDNF does not completely reverse the protective effect of BDNF-AS down-regulation on apoptosis. Thus, BDNF-AS knockdown can protect retinal cells under diabetic conditions via BDNF-associated pathways, and may provide a new therapeutic target for the treatment of diabetes-associated retinal degeneration.

Interactions between miRNAs and lncRNAs in DR
MIAT–VEGF cross-talk occurs via competition for miR-150-5p binding in ECs
Recently, a hypothesis on ceRNA proposed that mRNAs and lncRNAs communicate with, and co-regulate each other. Thus, lncRNAs can act as miRNA sponges, regulating the miRNAs available for target mRNA binding [133]. The ceRNA may exhibit gene regulatory properties by competing with the mRNA for a shared set of miRNAs, thereby regulating the translation of their antagonist [134]. In their study, Yan et al. [98] put forward a model that includes lncRNA–MIAT, miR-150-5p, and VEGF mRNA. In diabetic rats, hyperglycemia significantly up-regulates MIAT levels; miR-150-5p knockdown can further increase MIAT levels. MIAT and miR-150-5p are coexpressed in the nuclei of RF/6A cells. Furthermore, miR-150-5p regulates MIAT in the nucleus in an Ago2-dependent manner. Additionally,
MIAT overexpression significantly increases the level of VEGF, which is the target of \(\text{miR-150-5p}\) and is gradually reduced when \(\text{miR-150-5p}\) is up-regulated. In conclusion, during angiogenesis, MIAT can bind to the same site as \(\text{miR-150-5p}\), thus alleviating the effect of \(\text{miR-150-5p}\) repression and up-regulating the level of VEGF. MIAT functions as a ceRNA and forms a feedback loop with VEGF, while \(\text{miR-150-5p}\) regulates EC function in response to HG.

**MIAT-miR-29b-Sp1 counteraction loop in HG-treated Muöller cells**

Sp1 expression is directly targeted by \(\text{miR-29b}\), which is bound to the \(\text{miR-29b}\) promoter and represses the expression of \(\text{miR-29b}\) [135]. Concurrently, \(\text{miR-29b}\) inhibits the transcription of Sp1 [136]. In a new study, the expression of Sp1 was significantly increased in HG-induced rat rMC-1, which was accompanied by the up-regulation of MIAT and the down-regulation of \(\text{miR-29b}\) [99]. MIAT knockdown significantly reverses the low expression of \(\text{miR-29b}\), and high expression of Sp1, induced by HG. These results indicate that MIAT can regulate the expression of \(\text{miR-29b}\) and Sp1 via harboring of \(\text{miR-29b}\). The suppression of MIAT reverses the significant decrease in cell survival rate and increased cellular apoptosis induced by HG. Moreover, \(\text{miR-29b}\) knockdown significantly reverses the effects of cell survival and apoptosis mediated by MIAT suppression, which indicates that \(\text{miR-29b}\) knockdown interferes with the protective function of MIAT suppression. Thus, MIAT-controlled cellular apoptosis in DR may partly occur through absorption of \(\text{miR-29b}\) and inhibition of its function, as well as via regulation of expression of Sp1.

**The RNCR3/KLF2/miR-185-5p regulatory network modulates function of RECs**

RNCR3 can act as a ceRNA, forming a feedback loop with Kruppel-like factor 2 (KLF2) and \(\text{miR-185-5p}\) to regulate HUVEC and vascular smooth muscle cells (VSMC) [105]. This study aimed to determine whether \(\text{miR-185-5p}\) regulates the level of RNCR3 in RF/6A cells. They found that injecting a \(\text{miR-185-5p}\) mimic significantly decreases the expression of RNCR3 and KLF2 in RF/6A cells. Transfection of a \(\text{miR-185-5p}\) mimic significantly decreases cell viability and inhibits proliferation of RF/6A cells. RNCR3 knockdown significantly decreases the viability and proliferation of RF/6A cells, whereas KLF2 overexpression reverses these effects. Thus, the RNCR3/KLF2/miR-185-5p regulatory network is involved in the regulation of RF/6A cellular function.

**Conclusion and perspectives**

DR is a complication of DM, with multiple underlying pathogenic mechanisms, stemming from a variety of risk factors. A better understanding of the molecular mechanisms will help identify novel and effective targets for diagnosis and therapy. In recent years, miRNAs and IncRNAs have gained the attention of researchers in many fields including cancer, chronic diseases, and related complications. A number of miRNAs have been investigated and identified in the pathogenesis of DR, and a growing number of IncRNAs are being explored and studied with respect to their biological functions.

Presently, miRNAs represent a new powerful class of gene expression modulators in almost all human diseases. The involvement of miRNAs in the pathogenic mechanisms of DR was reported by microarray expression profiling studies, and specific roles of several aberrant miRNAs have been elucidated. The potential ability of a single miRNA to regulate several target genes, thus, influencing different molecular signaling pathways, has also been demonstrated. Amongst these, \(\text{miR-200b}\), \(\text{miR-146a}\), and \(\text{miR-126}\) have been most studied in the pathogenic processes of DR such as angiogenesis, inflammatory pathways, and oxidative stress (Figure 1). These miRNAs are considered potential biomarkers in the diagnosis and therapeutic targeting of DR. Although the number of studies is growing, the role of miRNAs, in a complex biological event such as DR, needs to be understood further; other miRNAs, and their target genes involved in this pathological event, are yet to be discovered.

In addition to miRNAs, IncRNAs have also been implicated in DR. However, the roles of IncRNAs in the pathogenesis of DR are far from being understood. Similarly, microarray analysis and RNA sequencing provide convenient and comprehensive approaches for identifying IncRNAs aberrantly expressed in DR. Moreover, the roles of specific IncRNAs, in the development of DR, are explored by investigating their involvement in targeting of different mRNAs and cross-talking with miRNAs. Most IncRNAs, mentioned in this review, were identified by consulting relevant studies about diseases that share the same etiology or pathogenesis. For example, ANRIL is significantly associated with increased susceptibility to type 2 DM [125]; thus, it is of no surprise that this aberrantly expressed IncRNA may be relevant in the molecular mechanisms underlying DR [129]. Systematic identification of IncRNAs, and a better understanding of their mechanisms of action, can pave the way for early diagnosis and improved therapeutics for DR. New candidate IncRNA genes, and their molecular mechanisms, remain to be explored.
Figure 1. Major miRNAs associated with the pathogenesis of DR
The main miRNAs involved in the progression, and contribution to DR, both in vitro and in vivo studies. The potential mechanisms of specific miRNAs (miR-126, miR-200b, miR-146a, miR-195, miR-15/miR16, and miR-29b) are demonstrated (see text for more details).

As discussed in this review, miRNAs and most lncRNAs regulate specific protein activity, and may, thus, represent potential targets for drugs that are more refined and less toxic than conventional protein-targetting drugs. Intensive research will inspire new hypotheses about pathogenesis and will lead to novel clinical applications. Understanding the roles of these molecules in DR will help develop novel strategies to effectively treat this disease and decrease the rate of patients developing blindness due to progression of retinopathy.

Acknowledgements
The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Funding
This work was supported by the National Natural Science Foundation of China [grant number 81670871].

Author contribution
Q.G. and G.S. designed the manuscript. Q.G. wrote the manuscript and collected the literature. G.S. critically revised the manuscript and provided the funding. The authors have read and approved the final manuscript.

Competing interests
The authors declare that there are no competing interests associated with the manuscript.

Abbreviations
ADA, adenosine deaminase; AGA, amadori-glycated albumin; Ago, argonaute; AGT, angiotensinogen; AKT3, serine/threonine-protein kinase 3; Ang-2, angiopoietin-2; ANRIL, antisense RNA to INK4 locus; ASM, acid sphingomyelinase; BDNF-AS, brain-derived neurotrophic factor antisense; BRB, blood–retinal barrier; CARD10, caspase-recruitment domain containing protein 10; ceRNA, competing endogenous RNA; CNV, choroidal neovascularization; DAXX, death domain associated protein; DM, diabetes mellitus; DR, diabetic retinopathy; EC, endothelial cell; ECM, extracellular matrix; ERK, extracellular signal regulated kinase; EV, extracellular vesicle; FN, fibronectin; FVM, fibrovascular membranes; GPCR, G-protein-coupled
References

1. Schwartz, S.S., Epstein, S., Corkey, B.E., Grant, S.F.A., Gavin, Ll., J.R., Aguilar, R.B. et al. (2017) A unified pathophysiological construct of diabetes and its complications. Trends Endocrinol. Metab. 28, 645–655

2. Antonetti, D.A., Klein, R. and Gardner, T.W. (2012) Diabetic retinopathy. N. Engl. J. Med. 366, 1227–1239

3. Ciulla, T.A., Amador, A.G. and Zimmerman, B. (2003) Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 26, 2653–2664

4. Frank, R.N. (2004) Diabetic retinopathy. N. Engl. J. Med. 350, 48–58

5. Shin, E.S., Sorenson, C.M. and Sheibani, N. (2014) Diabetes and retinal vascular dysfunction. J. Ophthalmic Vis. Res. 9, 362–373

6. Prunty, M.C., Aung, M.H., Hanif, A.M., Allen, R.S., Chenk, M.A., Boatright, J.H. et al. (2015) In vivo imaging of retinal oxidative stress using a reactive oxygen species-activated fluorescent probe. Invest. Ophthalmol. Vis. Sci. 56, 5862–5870

7. Saif, S.Z., Ovist, R., Kumar, S., Batmumlaie, K. and Ismail, I.S. (2014) Molecular mechanisms of diabetic retinopathy, general preventive strategies, and novel therapeutic targets. Biomed Res. Int. 2014, 901269

8. Sasongo, M.B., Wong, T.Y., Jenkins, A.J., Nguyen, T.T., Shaw, J.E. and Wang, J.J. (2015) Circulating markers of inflammation and endothelial function, and their relationship to diabetic retinopathy. Diabet. Med. 32, 686–691

9. Koleva-Georgieva, D.N., Sivkova, N.P. and Terzieva, D. (2011) Serum inflammatory cytokines IL-1beta, IL-6, TNF-alpha and VEGF have influence on the development of diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 52, 1156–1163

10. Ola, M.S., Nawaz, M.I., Khan, H.A. and Alhomida, A.S. (2013) Neurodegeneration and neuroprotection in diabetic retinopathy. Int. J. Mol. Sci. 14, 2559–2572

11. Kowluru, R.A. (2017) Diabetic retinopathy, metabolic memory and epigenetic modifications. Vision Res., doi:10.1016/j.visres.2017.02.011

12. Kowluru, R.A., Kowluru, A., Mishra, M. and Kumar, B. (2015) Oxidative stress and epigenetic modifications in the pathogenesis of diabetic retinopathy. Prog. Retin. Eye Res. 48, 40–61

13. Behl, T. and Kottwani, A. (2015) Exploring the various aspects of the pathological role of vascular endothelial growth factor (VEGF) in diabetic retinopathy. Pharmacol. Res. 99, 137–148

14. Ibrahim, A.S., Tawfik, A.M., Hussein, K.A., Markand, S., Rizk, N. et al. (2015) Pigment epithelium-derived factor inhibits retinal endothelial growth factor receptor; GWAS, genome-wide association study; HG, high glucose; HIF-1α, hypoxia-inducible factor-1α; HREC, human retinal EC; ICAM-1, intercellular adhesion molecule-1; IGF, insulin-like growth factor; IGF1R, IGF-1 receptor; INL, inner nuclear layer; IRAK1, IL-1 receptor associated kinase 1; KLF2, Kruppel-like factor 2; lncRNA, long noncoding RNA; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; MAPK, mitogen-activated protein kinase; MEG3, maternally expressed gene 3; MIFN2, mitofusin 2; MIAT, myocardial infarction associated transcript; MMP-9, matrix metalloproteinase 9; MSC, mesenchymal stem cell; MyDB8, myeloid differentiation primary-response protein-88; ncRNA, noncoding RNA; NPDR, non-proliferative DR; NV, neovascularization; OIR, oxygen-induced retinopathy; PDR, proliferative DR; PKR, RNA-dependent protein kinase; PRC2, polycomb repressor complex 2; pri-miRNA, primary miRNA; PVD, proliferative vitreoretinal disease; RAX, PKR-associated protein X; REC, retinal EC; RGC, retinal ganglion cell; RISC, RNA-induced silencing complex; rMC-1, retinal Müller cell; ROS, reactive oxygen species; RPE, retinal pigment epithelial; SAA3, serum amyloid antigen 3; SIRT1, silent information regulator protein 1; SOX2OT, SOX2 overlapping transcript; STAT3, signal transducer and activator of transcription 3; STZ, streptozotocin; TGF-β1, transforming growth factor β1; TLR, toll-like receptor; TNF, tumor necrosis factor; TRAF6, TNF receptor associated factor 6; VEGF, vascular endothelial growth factor; VSMC, vascular smooth muscle cell.
28 Cunha-Vaz, J.G. and Travassos, A. (1984) Breakdown of the blood-retinal barriers and cystoid macular edema. Surv. Ophthalmol. 28, 485–492
29 Aronson, D. and Rayfield, E.J. (2002) How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc. Diabetol. 1, 1
30 Strauss, O. (2005) The retinal pigment epithelium in visual function. Physiol. Rev. 85, 845–881
31 Miyamoto, N., de Kozak, Y., Jeanny, J.C., Gitton, A., Mascarelli, F., Massin, P. et al. (2007) Placental growth factor-1 and epithelial haemato-retinal barrier breakdown: potential implication in the pathogenesis of diabetic retinopathy. Diabetologia 50, 461–470
32 Kovacs, B., Lumayag, S., Cowan, C. and Xu, S. (2011) MicroRNAs in early diabetic retinopathy in streptozotocin-induced diabetic rats. Invest. Ophthalmol. Vis. Sci. 52, 4402–4409
33 He, L., He, X., Lowe, S.W. and Hannon, G.J. (2007) microRNAs join the p53 network--another piece in the tumour-suppression puzzle. Nat. Rev. Cancer 7, 819–822
34 Wu, J.H., Gao, Y., Ren, A.J., Zhao, S.H., Zhong, M., Peng, Y.J. et al. (2012) Altered microRNA expression profiles in retinas with diabetic retinopathy. Ophthalmic Res. 47, 195–201
35 Xiong, F., Du, X., Hu, J., Li, T., Du, S. and Wu, Q. (2014) Altered retinal microRNA expression profiles in early diabetic retinopathy: an in silico analysis. Curr. Eye Res. 39, 720–729
36 Gong, Q., Xie, J.n., Liu, Y., Li, Y. and Su, G. (2017) Differentially expressed microRNAs in the development of early diabetic retinopathy. J. Diabetes Res. 2017, 4727942
37 McArthur, K., Feng, B., Wu, Y., Chen, S. and Chakrabarti, S. (2011) MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. Diabetes 60, 1314–1323
38 Murray, A.R., Chen, Q., Takahashi, Y., Zhou, K.K., Park, K. and Ma, J.X. (2017) MicroRNA-200b downregulates oxidation resistance 1 (Oxr1) expression in the retina of type 1 diabetes model. Invest. Ophthalmol. Vis. Sci. 58, 1689–1697
39 Jiang, Q., Zhao, F., Liu, X., Li, R. and Liu, J. (2015) Effect of miR-200b on the development of diabetic retinopathy by targeting VEGF-A gene. Invest. Ophthalmol. Vis. Sci. 56, 419–426
40 Li, E.H., Huang, Q.Z., Li, G.C., Xiang, Z.Y. and Zhang, X. (2017) Effects of miRNA-200b on the development of diabetic retinopathy by targeting VEGF-A signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. U.S.A. 103, 12481–12486
41 Cowan, C., Muraleedharan, C.K., O'Donnell, I., Singh, P.K., Lum, H., Kumar, A. et al. (2014) MicroRNA-146 inhibits thrombin-induced NF-kappaB activation and subsequent inflammatory responses in human retinal endothelial cells. Invest. Ophthalmol. Vis. Sci. 55, 4944–4951
42 Ye, E.A. and Steinle, J.J. (2016) miR-146a mediates extracellular matrix protein production in chronic diabetes complications. Diabetes 65, 2975–2984
43 Ye, E.A. and Steinle, J.J. (2017) miR-146a attenuates inflammatory pathways mediated by TLR4/NF-kappaB and TNFalpha to protect primary human retinal microvascular endothelial cells grown in high glucose. Molecules 2016, 3958453
44 Wang, Q., Bozack, S.N., Yan, Y., Boulton, M.E., Grant, M.B. and Busik, J.V. (2014) Regulation of retinal inflammation by rhythmic expression of miR-146a in diabetic retina. Invest. Ophthalmol. Vis. Sci. 55, 3986–3994
45 Zhuang, P., Muraleedharan, C.K. and Xu, S. (2017) Intracellular delivery of miR-146b-3p regulates retinal inflammatory response in diabetic rat model. Exp. Biol. Med. 342, 1180–1190
46 Fong, B., Chen, S., McArthur, K., Wu, Y., Sen, S., Ding, Q. et al. (2011) miR-146b-3p regulates extracellular matrix protein production in chronic diabetes complications. Diabetes 60, 2975–2984
47 Ye, E.A. and Steinle, J.J. (2017) miR-146a suppresses STAT3/VEGF pathways and reduces apoptosis through IL-6 signaling in primary human retinal microvascular endothelial cells in high glucose conditions. Vision Res., doi:10.1016/j.visres.2017.03.009
48 Fulzele, S., El-Sherbini, A., Ahmad, S., Sangani, R., Matragoon, S., El-Remessy, A. et al. (2015) MicroRNA-146b-3p regulates retinal inflammation by suppressing adenosine deaminase-2 in diabetes. Bio. Med. Res. Int. 2015, 846501
49 Samra, Y.A., Saleh, H.M., Hussein, K.A., Elsherbiny, N.M., Ibrahim, A.S., Elmasry, K. et al. (2017) Adenosine deaminase-2-induced hyperpermeability in human retinal vascular endothelial cells is suppressed by microRNA-146b-3p. Invest. Ophthalmol. Vis. Sci. 58, 933–943
50 Bai, Y., Bai, X., Wang, Z., Zhang, X., Ruan, C. and Miao, J. (2011) MicroRNA-126 inhibits ischemia-induced retinal neovascularization via regulating angiogenic growth factors. Exp. Mol. Pathol. 91, 471–477
51 Ye, P., Liu, J., He, F., Xu, W. and Yao, K. (2014) Hypoxia-induced deregulation of miR-126 and its regulative effect on VEGF and MMP-9 expression. Int. J. Med. Sci. 11, 17–23
52 Mazzeto, A., Beltramo, E., Lavello, A., Carpanetto, A. and Porta, M. (2015) Molecular mechanisms of extracellular vesicle-induced vessel destabilization in diabetic retinopathy. Acta Diabetol. 52, 1113–1119
53 Rezk, N.A., Sabbah, N.A. and Saad, M.S. (2016) Role of microRNA-126 in screening, diagnosis, and prognosis of diabetic patients in Egypt. JUBMB Life 68, 452–458
54 Barutta, F., Bruno, G., Matullo, G., Chaturvedi, N., Grimaldi, S., Schalkwijk, C. et al. (2017) MicroRNA-126 and micro-/macrovacular complications of type 1 diabetes in the EURODIAB Prospective Complications Study. Acta Diabetol. 54, 133–139
55 Silva, V.A., Polesskaya, A., Sousa, T.A., Correa, V.M., Andre, N.D., Reis, R.I. et al. (2011) Expression and cellular localization of microRNA-29b and RAX, an activator of the RNA-dependent protein kinase (PKR), in the retina of streptozotocin-induced diabetic rats. Mol. Vis. 17, 2228–2240
56 Lin, X., Zhou, X., Liu, D., Yun, L., Zhang, L., Chen, X. et al. (2016) MicroRNA-29 regulates high-glucose-induced apoptosis in human retinal pigment epithelial cells through PTEN. In Vitro Cell. Dev. Biol. Anim. 52, 419–426

(© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
Hou, Q., Zhou, L., Tang, J., Ma, N., Xu, A., Tang, J. et al. (2016) LGR4 is a direct target of microRNA-34a and modulates the proliferation and migration of retinal pigment epithelial cells.

Zhang, R., Garrett, Q., Zhou, H., Wu, X., Mao, Y., Cui, X. et al. (2017) Upregulation of microRNA-34a regulates cell proliferation and migration of retinal pigment epithelial cells.

Tang, W.X., Wu, W.H., Zeng, X.X., Bo, H. and Huang, S.M. (2012) Early protective effect of mitofusion 2 overexpression in STZ-induced diabetic rat models.

Ye, E.A., Liu, L., Jiang, Y., Jan, J., Gaddipati, S., Suvas, S. et al. (2016) Dual anti-inflammatory and anti-angiogenic action of microRNA-34a in diabetic retinopathy.

Fouda, A.Y., Artham, S., El-Remessy, A.B. and Fagan, S.C. (2016) Renin-angiotensin system as a potential therapeutic target in stroke and retinopathy.

Zhang, L.Q., Cui, H., Wang, L., Fang, X. and Su, S. (2017) Role of microRNA-29a in the development of diabetic retinopathy by targeting AGT gene in a diabetic kidney.

Ye, E.A. and Steinle, J.J. (2015) miR-155/16 protects primary human retinal microvascular endothelial cells against hyperglycemia-induced increases in cell injury by targeting mitofusin 2 in diabetic rats.

Zeng, J., Xiong, Y., Li, G., Liu, M., He, T., Tang, Y. et al. (2013) miR-21 regulates SIRT1-mediated changes in diabetic retinopathy.

Boyerinas, B., Park, S.M., Hau, A., Murmann, A.E. and Peter, M.E. (2010) The role of let-7 in cell differentiation and cancer.

Carninci, P., Kasukawa, T., Katayama, S., Gough, J., Frith, M.C., Maeda, N. et al. (2005) The transcriptional landscape of the mammalian genome.

Kapranov, P., Cheng, J., Dike, S., Nix, D.A., Duttagupta, R., Willingham, A.T. et al. (2007) RNA maps reveal new RNA classes and a possible function for pervasive transcription.
van Heesch, S., van Iterson, M., Jacobi, J., Boymans, S., Essens, P.B., de Bruijn, E. et al. (2014) Extensive localization of long noncoding RNAs to the cytosol and mono- and polyribosomal complexes. Genome Biol. 15, R6

Guttman, M., Amit, I., Garber, M., French, C., Lin, M.F., Feldser, D. et al. (2009) Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 458, 223–227

Guttman, M., Donaghey, J., Carey, B.W., Garber, M., Grenier, J.K., Munson, G. et al. (2011) IncRNAs act in the circuity controlling pluriptenome and differentiation. Nature 477, 295–300

Washietl, S., Hofacker, I.L., Lukasser, M., Huttenhofer, A. and Stadler, P.F. (2005) Mapping of conserved RNA secondary structures predicts thousands of functional noncoding RNAs in the human genome. Nat. Biotechnol. 23, 1383–1390

Pedersen, J.S., Bejerano, G., Siepel, A., Rosenbloom, K., Lindblad-Toh, K., Lander, E.S. et al. (2006) Identification and classification of conserved RNA secondary structures in the human genome. PLoS Comput. Biol. 2, e33

Wang, K.C. and Chang, H.Y. (2011) Molecular mechanisms of long noncoding RNAs. Mol. Cell 43, 904–914

Mercer, T.R. and Mattick, J.S. (2013) Structure and function of long noncoding RNAs in epigenetic regulation. Nature Struct. Mol. Biol. 20, 300–307

Wapinski, O. and Chang, H.Y. (2011) Long noncoding RNAs and human disease. Trends Cell Biol. 21, 354–361

Ilshii, N., Ozaki, K., Sato, H., Mizuno, H., Saito, S., Takahashi, A. et al. (2006) Identification of a novel non-coding RNA, MIAT, that confers risk of myocardial infarction. J. Hum. Genet. 51, 1087–1099

Blackshaw, S., Harpavat, S., Trimarchi, J., Cai, L., Huang, H., Kuo, W.P. et al. (2004) Genomic analysis of mouse retinal development. PLoS Biol. 2, e247

Yan, B., Yao, J., Liu, J.Y., Li, X.M., Wang, X.Q., Li, Y.J. et al. (2015) lncRNA-MIAT regulates microvascular dysfunction by functioning as a competing endogenous RNA. Circ. Res. 116, 1143–1156

Zhang, J., Chen, M., Chen, J., Lin, S., Cai, D., Chen, C. et al. (2017) Long non-coding RNA MIAT acts as a biomarker in diabetic retinopathy by absorbing miR-29b and regulating cell apoptosis. Biochim. Biophys. Acta 1862, 791–801

101 Liu, J.Y., Yao, J., Li, X.M., Wang, X.Q., Wang, Y.N., Yang, H., Yao, M.D. et al. (2016) Role of long non-coding RNA-RNCR3 in atherosclerosis-related vascular dysfunction. Cell Death Dis. 5, e1506

Wallace, C., Smyth, D.J., Maisuria-Armer, M., Walker, N.M., Todd, J.A. and Clayton, D.G. (2010) The imprinted DLK1-MEG3 gene region on chromosome 14q32.2 alters susceptibility to type 1 diabetes. Nat. Genet. 42, 68–71

Andrew, T., Maniatis, N., Carbonaro, F., Liew, S.H., Lau, W., Spector, T.D. et al. (2008) Identification and replication of three novel myopia common susceptibility gene loci on chromosome 3q26 using linkage and linkage disequilibrium mapping. PLoS Genet. 4, e1000220

Sanuki, R., Onishi, A., Koke, C., Muramatsu, R., Watanabe, S., Muranishi, Y. et al. (2011) miR-124a is required for hippocampal axogenesis and retinal cone survival through Lhx2 suppression. Nat. Neurosci. 14, 1125–1134

Shan, K., Jiang, Q., Wang, X.Q., Wang, Y.N., Yang, H., Yao, M.D. et al. (2016) Role of long non-coding RNA-RNCR3 in atherosclerosis-related vascular dysfunction. Cell Death Dis. 7, e2248

Bochenek, G., Hasler, R., El Mohktari, N.E., Konig, I.R., Loos, B.G., Jepsen, S. et al. (2013) The large non-coding RNA ANRIL, which is associated with atherosclerosis, periodontitis and several forms of cancer, regulates ADIPOR1, VAMP3 and C11ORF10. Hum. Mol. Genet. 22, 4516–4527

107 Ola, M.S., Nawaz, M.I., El-Aasar, A.A., Abuamrah, M. and Alhomida, A.S. (2013) Reduced levels of brain derived neurotrophic factor (BDNF) in the serum of diabetic retinopathy patients and in the retina of diabetic rats. Cell. Mol. Neurobiol. 33, 359–367

Kaviarasan, K., Jithu, M., Arif Mulla, M., Sharma, T., Sivasankar, S., Das, U.N. et al. (2015) Low blood and vitreal BDNF, LXA4 and altered Th1/Th2 cytokine balance are potential risk factors for diabetic retinopathy. Metabolism 64, 958–966

109 Awata, T., Yamashita, H., Kurihara, S., Morita-Ohkubo, T., Miyashita, Y., Katayama, S. et al. (2015) Correction: A genome-wide association study for type 2 diabetes identifies a new susceptibility gene loci on chromosome 14q32.2 alters susceptibility to type 1 diabetes. Nat. Genet. 47, 1114–1116

Michalik, K.M., You, X., Manavski, Y., Doddballapur, A., Zornig, M., Braun, T. et al. (2014) Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth. Circ. Res. 114, 1389–1397

112 Puthanveetil, P., Chen, S., Feng, B., Gautam, A. and Chakrabarti, S. (2015) Long non-coding RNA MALAT1 regulates hyperglycaemia induced inflammatory process in the endothelial cells. J. Cell. Mol. Med. 19, 1418–1425

113 Zhou, Y., Zhang, X. and Klibanski, A. (2012) MEG3 noncoding RNA: a tumor suppressor. J. Mol. Endocrinol. 48, R45–R53

114 Mondal, T., Subhash, S., Vaid, R., Enroth, S., Uday, S., Reinus, B. et al. (2015) MEG3 long noncoding RNA regulates the TGF-beta pathway genes through formation of RNA-DNA triplex structures. Nat. Commun. 6, 7743

115 Kameswaran, V., Bramswig, N.C., McKenna, L.B., Penn, M., Schug, J., Hand, N.J. et al. (2014) Epigenetic regulation of the DLK1-MEG3 microRNA cluster in human type 2 diabetic islets. Cell Metab. 19, 135–145

116 Qiu, G.Z., Tian, W., Fu, H.T., Li, C.P., and Liu, B. (2016) Long noncoding RNA-MEG3 is involved in diabetes mellitus-related microvascular dysfunction. Biochem. Biophys. Res. Commun. 471, 135–141

117 Fantes, J., Nagle, N.K., Reyne, S.A., McIlveen, N.I., Collin, J.R., Howard-Peebles, P.N. et al. (2003) Mutations in SOX2 cause anophthalmia. Nat. Genet. 33, 461–463

118 London, A., Bemhar, I. and Schwartz, M. (2013) The retina as a window to the brain-from eye research to CNS disorders. Nat. Rev. Neuro. 9, 44–53

119 Li, C.P., Wang, S.H., Wang, W.Q., Song, S.G. and Liu, X.M. (2017) Long noncoding RNA-Sex20T knockdown alleviates diabetes mellitus-induced retinal ganglion cell (RGC) injury. Cell. Mol. Neurobiol. 37, 361–369

120 Liu, C., Li, C.P., Wang, J.J., Shan, K., Liu, X. and Yan, B. (2016) RNCR3 knockdown inhibits diabetes mellitus-induced retinal reactive gliosis. Biochem. Biophys. Res. Commun. 479, 198–203
Shan, K., Li, C.P., Liu, C., Liu, X. and Yan, B. (2017) RNCR3: a regulator of diabetes mellitus-related retinal microvascular dysfunction. *Biochem. Biophys. Res. Commun.* **482**, 777–783

Broadbent, H.M., Peden, J.F., Lorkowski, S., Goel, A., Ongen, H., Green, F. et al. (2008) Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs in the ANRIL locus on chromosome 9p. *Hum. Mol. Genet.* **17**, 806–814

Burdon, K.P., Macgregor, S., Hewitt, A.W., Sharma, S., Chidlow, G., Mills, R.A. et al. (2011) Genome-wide association study identifies susceptibility loci for open angle glaucoma at TMC01 and CDKN2B-AS1. *Nat. Genet.* **43**, 574–578

Companioni, O., Rodríguez Esparragon, F., Fernandez-Aceituno, A.M. and Rodríguez Perez, J.C. (2011) Genetic variants, cardiovascular risk and genome-wide association studies. *Rev. Esp. Cardiol.* **64**, 509–514

Cugino, D., Gianfagna, F., Santimone, I., de Gaetano, G., Donati, M.B., Iacoviello, L. et al. (2012) Type 2 diabetes and polymorphisms on chromosome 9p21: a meta-analysis. *Nutr. Metab. Cardiovasc. Dis.* **22**, 619–625

Cunnington, M.S., Santibanez Koref, M., Mayosi, B.M., Burn, J. and Keavney, B. (2010) Chromosome 9p21 SNPs associated with multiple disease phenotypes correlate with ANRIL expression. *PLoS Genet.* **6**, e1000899

Popov, N. and Gil, J. (2010) Epigenetic regulation of the INK4b-ARF-INK4a locus: in sickness and in health. *Epigenetics* **5**, 685–690

Sato, K., Nakagawa, H., Tajima, A., Yoshida, K. and Inoue, I. (2010) ANRIL is implicated in the regulation of nucleus and potential transcriptional target of E2F1. *Oncol. Rep.* **24**, 701–707

Thomas, A.A., Feng, B. and Chakrabarti, S. (2017) ANRIL: a regulator of VEGF in diabetic retinopathy. *Invest. Ophthalmol. Vis. Sci.* **58**, 470–480

Modarresi, F., Faghihi, M.A., Lopez-Toledano, M.A., Fatemi, R.P., Magistri, M., Brothers, S.P. et al. (2012) Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation. *Nat. Biotechnol.* **30**, 453–459

Li, Y., Xu, F., Xiao, H. and Han, F. (2017) Long noncoding RNA BDNF-AS inversely regulated BDNF and modulated high-glucose induced apoptosis in human retinal pigment epithelial cells. *J. Cell. Biochem.* **doi:10.1002/jcb.26245

Xu, L., Zhang, Z., Xie, T., Zhang, X. and Dai, T. (2016) Inhibition of BDNF-AS provides neuroprotection for retinal ganglion cells against ischemic injury. *PLoS ONE* **11**, e0164941

Tay, Y., Rinn, J. and Pandolfi, P.P. (2014) The multilayered complexity of ceRNA crosstalk and competition. *Nature* **505**, 344–352

Salmena, L., Poliseno, L., Tay, Y., Kats, L. and Pandolfi, P.P. (2011) A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? *Cell* **146**, 353–358

Jia, L.F., Huang, Y.P., Zhang, Y.F., Lu, M.Y., Wei, S.B., Meng, Z. et al. (2014) *miR-29b* suppresses proliferation, migration, and invasion of tongue squamous cell carcinoma through PTEN-AKT signaling pathway by targeting Sp1. *Oral Oncol.* **50**, 1062–1071

Yu, J., Luo, H., Li, N. and Duan, X. (2015) Suppression of type I collagen expression by *miR-29b* via PI3K, Akt, and Sp1 pathway, part II: an in vivo investigation. *Invest. Ophthalmol. Vis. Sci.* **56**, 6019–6028